{"id":"https://openalex.org/W2103196751","doi":"https://doi.org/10.1160/th10-05-0328","title":"Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay","display_name":"Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay","publication_year":2010,"publication_date":"2010-01-01","ids":{"openalex":"https://openalex.org/W2103196751","doi":"https://doi.org/10.1160/th10-05-0328","mag":"2103196751","pmid":"https://pubmed.ncbi.nlm.nih.gov/20978714"},"language":"en","primary_location":{"id":"doi:10.1160/th10-05-0328","doi":"https://doi.org/10.1160/th10-05-0328","is_oa":false,"landing_page_url":"https://doi.org/10.1160/th10-05-0328","pdf_url":null,"source":{"id":"https://openalex.org/S206235894","display_name":"Thrombosis and Haemostasis","issn_l":"0340-6245","issn":["0340-6245","2567-689X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320000","host_organization_name":"Thieme Medical Publishers (Germany)","host_organization_lineage":["https://openalex.org/P4310320000"],"host_organization_lineage_names":["Thieme Medical Publishers (Germany)"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Thrombosis and Haemostasis","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102004336","display_name":"Zhaoqing Wang","orcid":"https://orcid.org/0000-0003-1515-4945","observed_orcids":["https://orcid.org/0000-0003-1515-4945"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhaoqing Wang","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, New Jersey, USA","Bristol-Myers Squibb, Princeton, New Jersey, USA. yuchen.barrett@bms.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, New Jersey, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, New Jersey, USA. yuchen.barrett@bms.com","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103820467","display_name":"Charles E. Frost","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles Frost","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, New Jersey, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049683780","display_name":"Andrew Shenker","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew Shenker","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5110207659","display_name":"Yu Chen Barrett","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Yu Chen Barrett","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, New Jersey, USA. yuchen.barrett@bms.com","Bristol\u2010Myers Squibb  Princeton New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, New Jersey, USA. yuchen.barrett@bms.com","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Bristol\u2010Myers Squibb  Princeton New Jersey USA","institution_ids":["https://openalex.org/I4210091812"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5110207659"],"corresponding_institution_ids":["https://openalex.org/I4210091812"],"apc_list":null,"apc_paid":null,"fwci":42.1338,"has_fulltext":false,"cited_by_count":354,"citation_normalized_percentile":{"value":0.9984912,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"104","issue":"12","first_page":"1263","last_page":"1271"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10285","display_name":"Venous Thromboembolism Diagnosis and Management","score":0.5601000189781189,"subfield":{"id":"https://openalex.org/subfields/2724","display_name":"Internal Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10285","display_name":"Venous Thromboembolism Diagnosis and Management","score":0.5601000189781189,"subfield":{"id":"https://openalex.org/subfields/2724","display_name":"Internal Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":0.3905999958515167,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":0.0142000000923872,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/factor-xa-inhibitors","display_name":"factor Xa inhibitors","score":0.8870000243186951},{"id":"https://openalex.org/keywords/apixaban","display_name":"apixaban","score":0.9860000014305115},{"id":"https://openalex.org/keywords/prothrombin-time","display_name":"prothrombin time","score":0.8849999904632568},{"id":"https://openalex.org/keywords/international-normalized-ratio","display_name":"international normalized ratio","score":0.9620000123977661},{"id":"https://openalex.org/keywords/thromboplastin-reagents","display_name":"thromboplastin reagents","score":0.8519999980926514},{"id":"https://openalex.org/keywords/plasma-drug-concentration","display_name":"plasma drug concentration","score":0.5839999914169312},{"id":"https://openalex.org/keywords/venous-thromboembolism","display_name":"venous thromboembolism","score":0.9829999804496765},{"id":"https://openalex.org/keywords/anticoagulation-monitoring","display_name":"anticoagulation monitoring","score":0.7429999709129333},{"id":"https://openalex.org/keywords/assay-sensitivity","display_name":"assay sensitivity","score":0.47999998927116394}],"concepts":[{"id":"https://openalex.org/C2780638905","wikidata":"https://www.wikidata.org/wiki/Q414462","display_name":"Apixaban","level":5,"score":0.8898046016693115},{"id":"https://openalex.org/C2778261982","wikidata":"https://www.wikidata.org/wiki/Q1755136","display_name":"Partial thromboplastin time","level":3,"score":0.6347054243087769},{"id":"https://openalex.org/C2780434524","wikidata":"https://www.wikidata.org/wiki/Q1144385","display_name":"Prothrombin time","level":2,"score":0.615418553352356},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5640637874603271},{"id":"https://openalex.org/C144594695","wikidata":"https://www.wikidata.org/wiki/Q6153218","display_name":"Thromboplastin","level":3,"score":0.5461292862892151},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.49164873361587524},{"id":"https://openalex.org/C2778661090","wikidata":"https://www.wikidata.org/wiki/Q420262","display_name":"Rivaroxaban","level":4,"score":0.45676445960998535},{"id":"https://openalex.org/C19831878","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Therapeutic index","level":3,"score":0.4449707865715027},{"id":"https://openalex.org/C89838059","wikidata":"https://www.wikidata.org/wiki/Q623738","display_name":"Coefficient of variation","level":2,"score":0.4100402295589447},{"id":"https://openalex.org/C2778382381","wikidata":"https://www.wikidata.org/wiki/Q179217","display_name":"Coagulation","level":2,"score":0.40711677074432373},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.403707355260849},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2953184247016907},{"id":"https://openalex.org/C43617362","wikidata":"https://www.wikidata.org/wiki/Q170050","display_name":"Chromatography","level":1,"score":0.2861211597919464},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.2790759801864624},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.16530841588974},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.05801007151603699}],"mesh":[{"descriptor_ui":"D000069552","descriptor_name":"Rivaroxaban","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001777","descriptor_name":"Blood Coagulation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D001780","descriptor_name":"Blood Coagulation Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007555","descriptor_name":"Isoxazoles","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D009025","descriptor_name":"Morpholines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011237","descriptor_name":"Predictive Value of Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011517","descriptor_name":"Prothrombin Time","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D015203","descriptor_name":"Reproducibility of Results","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016903","descriptor_name":"Drug Monitoring","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019934","descriptor_name":"International Normalized Ratio","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D054556","descriptor_name":"Venous Thromboembolism","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D054556","descriptor_name":"Venous Thromboembolism","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D065427","descriptor_name":"Factor Xa Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1160/th10-05-0328","doi":"https://doi.org/10.1160/th10-05-0328","is_oa":false,"landing_page_url":"https://doi.org/10.1160/th10-05-0328","pdf_url":null,"source":{"id":"https://openalex.org/S206235894","display_name":"Thrombosis and Haemostasis","issn_l":"0340-6245","issn":["0340-6245","2567-689X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320000","host_organization_name":"Thieme Medical Publishers (Germany)","host_organization_lineage":["https://openalex.org/P4310320000"],"host_organization_lineage_names":["Thieme Medical Publishers (Germany)"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Thrombosis and Haemostasis","raw_type":"journal-article"},{"id":"pmid:20978714","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20978714","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Thrombosis and haemostasis","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W1878559559","https://openalex.org/W1968535664","https://openalex.org/W1973233314","https://openalex.org/W2018183727","https://openalex.org/W2027151097","https://openalex.org/W2045987573","https://openalex.org/W2052188302","https://openalex.org/W2066055694","https://openalex.org/W2067118403","https://openalex.org/W2067353872","https://openalex.org/W2071869524","https://openalex.org/W2072353311","https://openalex.org/W2077456487","https://openalex.org/W2091101264","https://openalex.org/W2110167268","https://openalex.org/W2113446992","https://openalex.org/W2114189419","https://openalex.org/W2123497121","https://openalex.org/W2137236165","https://openalex.org/W2156074347","https://openalex.org/W2157224841","https://openalex.org/W2157601282","https://openalex.org/W2161520144"],"related_works":["https://openalex.org/W4308054760","https://openalex.org/W2131569638","https://openalex.org/W2040812969","https://openalex.org/W2029696469","https://openalex.org/W1884576739","https://openalex.org/W4380769025","https://openalex.org/W2014616799","https://openalex.org/W2030637643","https://openalex.org/W3171234404","https://openalex.org/W3108232199"],"abstract_inverted_index":{"Apixaban":[0],"and":[1,14,49,63,83,114,182,184,205,218],"other":[2],"factor":[3],"Xa":[4],"(FXa)":[5],"inhibitors":[6,56,78,102,116],"are":[7],"in":[8,26,57,69,91,230],"late-stage":[9],"clinical":[10,209],"development":[11],"for":[12,164,197],"prevention":[13],"treatment":[15,234],"of":[16,30,41,122,126,140,179,187,190,243],"thromboembolic":[17],"diseases.":[18],"Although":[19],"routine":[20],"monitoring":[21],"will":[22],"not":[23],"be":[24,34],"required,":[25],"certain":[27],"situations":[28],"assessment":[29],"drug":[31,86],"level":[32],"may":[33],"helpful.":[35],"This":[36],"study":[37],"evaluated":[38,68,90],"the":[39,124,176,198,240],"suitability":[40],"commercially":[42],"available":[43],"prothrombin":[44],"time/international":[45],"normalised":[46],"ratio":[47,147],"(PT/INR)":[48],"anti-FXa":[50],"activity":[51,220,238],"assays":[52,66,159],"to":[53,132,153],"measure":[54],"FXa":[55,77,101,115,128,142,166],"plasma.":[58],"Twelve":[59],"PT":[60,146],"(ISI":[61],"0.89-1.88)":[62],"three":[64],"anti-Xa":[65,158,219,237],"were":[67,89],"vitro":[70],"using":[71],"human":[72],"plasma":[73,87,201,216,245],"spiked":[74],"with":[75,85,93,98,203,225],"four":[76],"(0-2,000":[79],"ng/ml).":[80],"Assay":[81],"variability":[82],"correlation":[84,213],"exposure":[88],"patients":[92,231],"venous":[94],"thromboembolism":[95],"(VTE)":[96],"treated":[97],"apixaban.":[99],"All":[100],"prolonged":[103],"PT;":[104],"however,":[105,168],"assay":[106,194],"sensitivity":[107],"was":[108,172,239],"dependent":[109],"on":[110,145],"thromboplastin":[111,135,150],"reagents":[112],"used":[113],"tested.":[117],"To":[118],"achieve":[119],"a":[120,141],"doubling":[121],"PT,":[123],"concentration":[125,217],"each":[127,165],"inhibitor":[129],"varied":[130,148],"2.6-":[131],"8-fold":[133],"between":[134,214],"reagents.":[136,151],"The":[137,211],"rank":[138,170],"order":[139,171],"inhibitor's":[143],"effect":[144],"across":[149],"Conversion":[152],"INR":[154],"increased":[155],"variability.":[156],"Different":[157],"showed":[160],"different":[161],"dynamic":[162,177],"ranges":[163],"inhibitor;":[167],"their":[169],"consistent.":[173],"For":[174],"apixaban,":[175],"range":[178],"<7.8-240":[180],"ng/ml,":[181],"inter-":[183],"intra-assay":[185],"precision":[186],"<6%":[188],"coefficient":[189],"variation":[191],"by":[192],"Rotachrom":[193],"appeared":[195],"suitable":[196],"anticipated":[199],"apixaban":[200,215,244],"concentrations":[202],"2.5":[204],"5":[206],"mg":[207],"bid":[208],"doses.":[210],"stronger":[212],"(r2":[221,227],"=":[222,228],"0.88-0.89)":[223],"compared":[224],"PT/INR":[226],"0.36)":[229],"undergoing":[232],"VTE":[233],"suggested":[235],"that":[236],"better":[241],"indicator":[242],"concentrations.":[246]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":8},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":13},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":10},{"year":2019,"cited_by_count":16},{"year":2018,"cited_by_count":17},{"year":2017,"cited_by_count":22},{"year":2016,"cited_by_count":32},{"year":2015,"cited_by_count":43},{"year":2014,"cited_by_count":49},{"year":2013,"cited_by_count":61},{"year":2012,"cited_by_count":39}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2016-06-24T00:00:00"}